SANTA MONICA, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will present a company overview at three upcoming investor conferences in May 2015:

  • Credit Suisse Antibody Day
     Wednesday, May 6, 2015, at 8:00am Local Time
    Credit Suisse Offices, New York, New York
     
  • Bank of America Merrill Lynch 2015 Health Care Conference
     Tuesday, May 12, 2015, at 1:40pm Local Time
    Encore at the Wynn, Las Vegas, Nevada
     
  • UBS Global Healthcare Conference
     Tuesday, May 19, 2015, at 8:30am Local Time
    Sheraton New York Times Square Hotel, New York, New York

The Company's corporate overview to be presented at the Credit Suisse Antibody Day will be available through the Calendar of Events section of the Company's website at ir.kitepharma.com.

Dr. Chang will also participate in the CAR-T Panel as part of the Piper Jaffray GenomeRx Symposium on Wednesday, May 20, 2015, at 10:25am Local Time at The New York Palace Hotel, New York, New York.

About Kite Pharma

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors.  Kite is based in Santa Monica, CA.

CONTACT: Kite Pharma
         Cynthia M. Butitta
         Chief Financial Officer and Chief Operating Officer
         310-824-9999
         
         For Media: Justin Jackson
         For Investor Inquiries: Lisa Burns and Carol Werther
         Burns McClellan
         212-213-0006
         jackson@burnsmc.com
         burns@burnsmc.com
         cwerther@burnsmc.com

Kite Pharma, Inc. logo